Welcome to our dedicated page for Xilio Therapeutics news (Ticker: XLO), a resource for investors and traders seeking the latest updates and insights on Xilio Therapeutics stock.
Xilio Therapeutics, Inc. (Nasdaq: XLO) is a biopharmaceutical company based in Waltham, Massachusetts, dedicated to pioneering tumor-activated immuno-oncology (I-O) therapies aimed at significantly improving outcomes for cancer patients. The company's name, Xilio, is derived from the Latin term 'ex nihilo,' meaning creation or big bang, symbolizing its innovative approach.
Xilio leverages its proprietary platform to develop a pipeline of novel, tumor-activated clinical and preclinical I-O molecules. These include engineered antibodies, cytokines, and chemokines, all designed to localize anti-tumor activity within the tumor microenvironment, thus optimizing the therapeutic index and minimizing systemic side effects.
Key Products and Developments:
- XTX202: An investigational tumor-activated, engineered IL-2 molecule designed to stimulate CD8+ effector T cells and natural killer (NK) cells without stimulating regulatory T cells. Recent Phase 1/2 data showed a 50% disease control rate at higher doses, and it is currently being evaluated in a Phase 2 trial for melanoma and renal cell carcinoma.
- XTX101: A tumor-activated, Fc-enhanced anti-CTLA-4 monoclonal antibody designed to block CTLA-4 and deplete regulatory T cells within the tumor microenvironment. It is being evaluated in combination with atezolizumab in a Phase 1/2 clinical trial for advanced solid tumors.
- XTX301: An engineered IL-12 molecule designed to boost anti-tumor immunity and convert 'cold' tumors into 'hot' ones. XTX301 is in a Phase 1 clinical trial, and Xilio has recently entered into an exclusive license agreement with Gilead Sciences for its development.
Recent Achievements:
- XTX202 Phase 1 monotherapy dose-escalation success at a dose level of 4.0 mg/kg, with plans to explore combination therapy opportunities.
- The company announced a strategic partnership with Gilead Sciences to accelerate the development of XTX301.
- Financial results indicate that Xilio's existing cash and cash equivalents can fund operations into the second quarter of 2025, bolstered by recent private placements and upfront payments from strategic partnerships.
For more detailed information on Xilio Therapeutics and its pipeline of tumor-activated I-O therapies, visit www.xiliotx.com.
Xilio Therapeutics, Inc. (Nasdaq: XLO) reported progress in its clinical pipeline and financial results for 2022. The company ended 2022 with $120.4 million in cash, expected to fund operations into Q2 2024. XTX202, a tumor-activated IL-2, showed promising early results in a Phase 1 trial, with plans to initiate a Phase 2 trial in April 2023. XTX301 and XTX101 are also in development, with preliminary data anticipated in 2023. However, net losses increased to $88.2 million for the year, up from $75.8 million in 2021, driven by R&D expenses, which grew to $59.2 million.
Xilio Therapeutics, a clinical-stage biotechnology company focused on tumor-activated immuno-oncology therapies, announced its participation in two investor conferences. The Cowen 43rd Annual Healthcare Conference will take place on March 6, 2023, at 9:10 a.m. ET, while the Oppenheimer 33rd Annual Healthcare Conference is scheduled for March 13, 2023, with a virtual presentation at 4:00 p.m. ET. Investors can access live webcasts on the Xilio Therapeutics website, with replays available for 30 days post-event. The company utilizes a proprietary platform to develop therapies aimed at improving cancer treatment outcomes without systemic side effects.
Xilio Therapeutics, a biotechnology firm specializing in immuno-oncology therapies, announced that CEO René Russo will speak at Citi’s 2023 Virtual Oncology Leadership Summit on February 23, 2023, at 9:00 a.m. ET. The live presentation will be available on the company's website, with a replay accessible for 30 days post-event. Xilio is focused on developing tumor-activated therapies aimed at improving cancer treatment outcomes while minimizing side effects. Their innovative approach utilizes proprietary technology to target anti-tumor activity specifically within the tumor microenvironment, with multiple programs currently in clinical and preclinical stages.
Xilio Therapeutics, Inc. (Nasdaq: XLO) announced that CEO René Russo will participate in a fireside chat at the Guggenheim Healthcare Talks Oncology Day on February 9, 2023, at 3:55 p.m. ET in New York. Investors can access a live webcast of the presentation through the Investors & Media section of the Xilio Therapeutics website. A recorded version will be available for 30 days post-event. The company focuses on developing tumor-activated immuno-oncology therapies to improve cancer treatment outcomes while reducing systemic side effects. Xilio is advancing multiple clinical and preclinical programs in this innovative area.
Xilio Therapeutics, Inc. (Nasdaq: XLO) will host a live virtual program on December 1, 2022, at 12:30 p.m. ET to discuss its clinical-stage molecule, XTX301, an engineered IL-12 aimed at treating immunologically 'cold' tumors. Dr. Diwakar Davar from UPMC Hillman Cancer Center will explain the significance of IL-12 in stimulating anti-tumor immunity and the differences between cold and hot tumors. Xilio executives will also outline the Phase 1 trial for XTX301 and its anticipated timeline. The event will include a Q&A session.
Xilio Therapeutics (Nasdaq: XLO) reported significant progress in its clinical-stage pipeline, showcasing tumor-activated therapies, XTX202 and XTX301. The ongoing Phase 1 trial for XTX202 has successfully reached a target dose of 1 mg/kg, showing increased CD8+ effector and NK cells without vascular leak syndrome. XTX301 received FDA IND clearance, with patient enrollment expected in early 2023. The company reported $139.1 million in cash as of September 30, 2022, which is projected to last until Q2 2024, despite a net loss of $19.8 million for Q3 2022.
Xilio Therapeutics, Inc. (Nasdaq: XLO) announced its participation in a virtual fireside chat at the Cowen 6th Annual IO Next Summit on November 11, 2022, at 1:40 p.m. ET. The event can be accessed via live webcast in the Investors & Media section of its website, with a replay available for 30 days post-presentation. Xilio focuses on developing tumor-activated immuno-oncology therapies, using its GPS platform to create biologics targeting the tumor microenvironment, aiming for enhanced anti-tumor activity. Key product candidates include XTX101 and XTX202.
On September 22, 2022, Xilio Therapeutics (Nasdaq: XLO) announced its participation in a fireside chat at the Guggenheim Nantucket Therapeutics Conference, scheduled for September 29, 2022, at 10:15 a.m. ET. A live webcast will be available on the company’s website, with access under the “Events & Presentations” section. This presentation will be archived for 30 days. Xilio is focused on developing tumor-selective immuno-oncology therapies aimed at improving cancer patient outcomes through its proprietary GPS platform.
Xilio Therapeutics has appointed Tomas J. Heyman to its board of directors, enhancing the team with nearly 40 years of biopharmaceutical leadership experience. Heyman previously worked at Johnson & Johnson, overseeing substantial investments in over 120 companies. Additionally, John Maraganore, former CEO of Alnylam Pharmaceuticals, joins as a strategic advisor. These appointments aim to advance Xilio's tumor-selective immunotherapy programs, leveraging their expertise to drive value creation and innovation in cancer treatment.
Xilio Therapeutics, a biotechnology company focused on immuno-oncology therapies, will participate in a virtual fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on September 13, 2022, at 2:55 p.m. ET. The event will be accessible via a live webcast on the company’s website, with a replay available for 30 days post-event. Xilio is advancing its proprietary GPS platform to engineer tumor-selective cytokines and checkpoint inhibitors, including clinical-stage programs XTX101 and XTX202.
FAQ
What is the current stock price of Xilio Therapeutics (XLO)?
What is the market cap of Xilio Therapeutics (XLO)?
What is Xilio Therapeutics, Inc.?
What does the name Xilio mean?
What are the key products developed by Xilio?
What is the focus of Xilio's technology platform?
What recent achievements has Xilio reported?
What is XTX202?
What is XTX101?
What is XTX301?
How can I learn more about Xilio Therapeutics?
What are the financial prospects of Xilio Therapeutics?
